Sirna Therapeutics (RNAI) Reports a Q3 Loss
Sirna Therapeutics Inc. (Nasdaq: RNAI) reports a Q3 loss of $0.13 compared to a net loss of $0.08 per share, for the same period in 2005.
Revenues for the third quarter of 2006 were $2.0 million compared to $1.9 million in the third quarter of 2005. Deferred revenues from collaboration partners, included on the balance sheet at September 30, 2006, were $9.7 million.
Revenues for the third quarter of 2006 were $2.0 million compared to $1.9 million in the third quarter of 2005. Deferred revenues from collaboration partners, included on the balance sheet at September 30, 2006, were $9.7 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Synopsys, Inc. (SNPS) Misses Q2 EPS by 2c; Issues Confident Q3 Outlook; Guides FY12
- Infoblox (BLOX) Tops Q3 EPS by 4c; Guides Q4
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
